Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2018-06-28 Earnings Release
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
CS Pharmanutra crescita record a maggio
Earnings Release Classification · 1% confidence The document is an Italian regulatory filing ('Informazione Regolamentata') dated June 28, 2018. The subject ('Oggetto') is 'CS Pharmanutra crescita record a maggio' (CS Pharmanutra record growth in May). The text announces record sales figures for May 2018, providing percentage growth figures for the Italian and international markets. This is a communication of recent financial performance highlights, not the full periodic report (like 10-K or IR). The structure, brevity, and focus on immediate results strongly suggest an Earnings Release (ER). Although it mentions 'Vedi allegato' (See attachment), the core content is the release of the results summary, making ER the most appropriate classification over RPA, as it contains the actual results summary, not just an announcement of a future release. Q2 2018
2018-06-28 Italian
CS NEW COMMERCIAL AGREEMENTS SIGNED FOR THE DISTRIBUTION OF SUCROSOMIAL IRON ABROAD
Regulatory Filings Classification · 1% confidence The document is an official communication from PharmaNutra S.p.A. filed on May 28, 2018, identified by the header "Informazione Regolamentata" (Regulated Information) and the type "REGEM". The subject is "NEW COMMERCIAL AGREEMENTS SIGNED FOR THE DISTRIBUTION OF SUCROSOMIAL IRON ABROAD". This document announces specific business developments (new distribution contracts) rather than releasing full periodic financial results (ER/IR), providing detailed governance structure (CGR), or reporting insider trades (DIRS). It is a specific business update that falls under general regulatory announcements. Since it is a specific announcement of commercial activity and not a standard periodic report (like 10-K or IR), and it doesn't fit the other specific categories (like DIV, CAP, MANG), the most appropriate classification is the general regulatory announcement category, RNS, as it is a formal disclosure to the market about a material event.
2018-05-28 English
CS SIGLATI NUOVI ACCORDI COMMERCIALI PER LA DISTRIBUZIONE DEL FERRO SUCROSOMIALE ALL’ESTERO
Regulatory Filings Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated May 28, 2018, identified by the header "Informazione Regolamentata n. 20106-8-2018" and the type "REGEM". The subject ("Oggetto") is "CS SIGLATI NUOVI ACCORDI COMMERCIALI PER LA DISTRIBUZIONE DEL FERRO SUCROSOMIALE ALL'ESTERO" (New Commercial Agreements Signed for the Distribution of Sucrosomial Iron Abroad). This document details the signing of new distribution agreements in Egypt and Poland, focusing on business expansion and commercial strategy. It is not a formal financial report (like 10-K or IR), an earnings release (ER), or a proxy statement. It is a specific business update concerning commercial activities and market expansion, which fits best under the general category of Regulatory Filings (RNS) as it is a mandatory disclosure, or potentially a general announcement. Given the content is a press release announcing business developments rather than a specific financial statement or management discussion, RNS (Regulatory Filings) is the most appropriate general classification for this type of market-sensitive, non-standardized announcement, although it functions like a press release. Since there is no specific code for 'Commercial Update' or 'Press Release', RNS serves as the best fit for a general regulatory announcement not covered by other specific codes.
2018-05-28 Italian
COMUNICATO STAMPA ASSEMBLEA DEGLI AZIONISTI APPROVAZIONE BILANCIO DEL 23/04/2018
AGM Information Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) dated April 23, 2018, concerning the outcomes of the Shareholders' Meeting (ASSEMBLEA DEGLI AZIONISTI). The key resolutions include the approval of the 2017 Financial Statements (BILANCIO D'ESERCIZIO), the decision to distribute a dividend (0.33 EUR per share), and changes to the Board of Directors (incremento ad 8 membri). Since the document summarizes the decisions made at the Annual General Meeting (AGM) and explicitly mentions the approval of the annual financial statements and dividend distribution, it strongly relates to AGM activities. While it touches upon financial results (ER/IR content), the primary context is the formal shareholder meeting and its resolutions. The closest fit among the provided codes is AGM-R (AGM Information), as it details the outcomes of that specific meeting. It is not the full 10-K, nor is it just an Earnings Release (ER), as it includes governance changes and dividend approval.
2018-04-23 Italian
CS PHARMANUTRA S.p.A. PUBBLICATO AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA
AGM Information Classification · 1% confidence The document is an official press release (CS) from Pharmanutra S.p.A. announcing the publication of the 'AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA' (Notice of Call for the Ordinary Shareholders' Meeting). The key subject matter is the summoning of a general meeting, which includes items like the approval of the 2017 financial statements and the nomination of a new Board Member. This type of notice, which informs the market about the upcoming meeting and where related documents (like proxy forms and financial statements) can be found, is directly related to shareholder meetings and voting procedures. While it announces an AGM, the document itself is the formal notice of the meeting, not the AGM presentation materials (AGM-R) or the proxy solicitation materials (PSI). Since it specifically concerns the calling of a general meeting and the agenda items, it is most closely related to the governance and shareholder meeting process. Given the options, the content strongly points towards the preparatory materials for a shareholder meeting. However, the core purpose is the official announcement of the meeting call. The closest fit among the provided codes for a formal notice regarding a general meeting, especially one that precedes the actual voting or presentation, is often related to proxy/governance materials. Since the agenda includes the approval of the annual accounts and board changes, and it is a formal notice, it relates to the governance structure and shareholder rights. The most specific category for materials related to shareholder meetings is PSI (Proxy Solicitation & Information Statement), as the notice details where to find the proxy forms and explanatory reports. Alternatively, it could be seen as a general regulatory announcement (RNS). Given the specific mention of the meeting and the availability of proxy forms, PSI is a strong candidate, but since this is the *notice of call* itself, and not the proxy statement, and it is a formal regulatory communication, RNS (Regulatory Filings) serves as a robust fallback for official notices that don't perfectly match the specific meeting materials (like the proxy statement itself or the AGM presentation). However, looking closely at the agenda items (approving the annual report and board changes), this is a mandatory step leading up to the AGM. If the document were the actual proxy statement, it would be PSI. If it were the presentation given at the meeting, it would be AGM-R. Since it is the formal notice of the meeting, it is a regulatory announcement about a corporate event. I will classify this as RNS as it is a general regulatory announcement regarding a corporate action (meeting call) that doesn't fit the specific material types (like the actual proxy or the AGM presentation). The document length is moderate (5300 chars), suggesting it is more than just a brief announcement of publication (RPA).
2018-04-06 Italian
COMUNICATO STAMPA: PHARMANUTRA OTTIENE IL BREVETTO PER IL CETILAR RM
Investor Presentation Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated April 6, 2018, identified by the header 'Informazione Regolamentata' (Regulated Information) and the subject 'COMUNICATO STAMPA' (PRESS RELEASE). The content details the granting of a patent for the product Cetilar® RM, which is an announcement concerning intellectual property and innovation. This type of announcement, which is a press release about a specific corporate event (patent grant), fits best under the general category of regulatory announcements that are not specifically financial reports (10-K, IR, ER) or management changes (MANG). Since the core subject is the confirmation of intellectual property rights, it relates to the company's assets and innovation. However, given the available codes, this is a specific corporate update that is not a standard financial filing, director dealing, or dividend notice. It is a formal announcement of a strategic asset acquisition (patent). While 'LTR' (Legal Proceedings Report) is related to legal matters, this is a positive patent grant, not a proceeding. The most fitting general category for a specific, non-standard corporate announcement that isn't a financial report or management change is 'RNS' (Regulatory Filings) as a catch-all for formal disclosures, or potentially 'IP' (Investor Presentation) if it were a presentation, but it is a press release. Given the nature of patent grants being crucial intellectual property news, and lacking a specific 'IP/Patent' code, 'RNS' serves as the appropriate regulatory disclosure fallback for this type of material that is not a core financial report or proxy material. The document length is moderate, but the content is a direct announcement, not a reference to a larger attached report, thus avoiding the RPA classification.
2018-04-06 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.